AKCEA-APOCIII-LRx inhibits the production of apolipoprotein C-III
(ApoC-III) for the broad population of patients who have cardiometabolic disease due to their elevated triglyceride levels and ApoC-III.
as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.
The study by Harvard School of Public Health (HSPH) researchers is the first research to show that a small protein, apolipoprotein C-III
(apoC-III), that sometimes resides on the surface of HDL cholesterol may increase the risk of heart disease and that HDL cholesterol without this protein may be especially heart protective.
Plasma apolipoprotein C-III
transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
7 December 2011 - US drug discovery and development company ISIS Pharmaceuticals Inc (NASDAQ:ISIS) reported on Tuesday positive data from a Phase I clinical trial with ISIS-APOCIIIRx, demonstrating that ISIS-APOCIIIRx treatment led to fast, dose-dependent reductions of up to 78% in apolipoprotein C-III
(apoC-III) protein and up to 44% in blood triglyceride levels.
Other atherogenic lipoprotein particles, including chylomicron and VLDL remnants, abnormal remnant composition, and increased apolipoprotein C-III
complicate the metabolic syndrome picture as well, said Dr.
Of the 18 differentially displayed proteins, 12 proteins (a-1B-glycoprotein, keratin type II, neurofilament triplet L protein, vitamin D-binding protein precursor, protease C1 inhibitor precursor, keratin type I cytoskeleton, complement factor B, complement C1r subcomponent precursor, transthyretin precursor, zinc finger protein 792, kininogen-1 precursor, and PRAME family member 7) decreased in concentration after TCC exercise; 4 proteins (complement factor H, apolipoprotein C-III
precursor, complement C3 precursor, and [[alpha].
Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III
(apoC-III) resides on the surface of triglyceride-rich lipoproteins (2) but is also present on HDL particles (3) and remnant-like particles (4).
Transferrin isoelectric focusing (TIEF) is generally applied in the screening for inborn errors in the biosynthesis of N-glycans, whereas apolipoprotein C-III
(apoC-III) isoelectric focusing (IEF) can be used in the screening for inborn errors in the biosynthesis of mucin-type core 1 O-glycans (1).
Major peaks are observed corresponding to IgG, albumin dimer, transferrin, albumin, doubly charged albumin, apolipoprotein A-I, transthyretin, apolipoprotein C-III
, apolipoprotein C-II, and apolipoprotein C-I.
Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III